Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ovid Therapeutics Inc OVID

Healthcare Biotechnology
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other... see more

Recent & Breaking News (NDAQ:OVID)

Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum

GlobeNewswire March 9, 2023

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

GlobeNewswire March 8, 2023

Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

GlobeNewswire February 28, 2023

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

GlobeNewswire February 8, 2023

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

GlobeNewswire January 5, 2023

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

GlobeNewswire December 2, 2022

Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

GlobeNewswire November 8, 2022

Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

GlobeNewswire September 27, 2022

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 7, 2022

Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

GlobeNewswire August 9, 2022

Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

GlobeNewswire June 6, 2022

Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

GlobeNewswire May 10, 2022

Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

GlobeNewswire April 8, 2022

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 15, 2022

Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

GlobeNewswire March 4, 2022

Healx and Ovid Therapeutics to Enter Strategic Partnership

GlobeNewswire February 8, 2022

Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators

GlobeNewswire January 3, 2022

Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results

GlobeNewswire November 10, 2021

Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors

GlobeNewswire October 7, 2021

Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 7, 2021